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1  |  INTRODUC TION
Food hypersensitivity (FHS)— a term which encompasses food allergy 
(both IgE- mediated and non– IgE- mediated mechanisms), coeliac disease 
and food intolerances— continues to be a major issue in terms of the sup-
ply of safe food for consumers. According to the UK’s Food Standards 
Agency (FSA), around 1 in 20 of the UK population report a FHS. Food 
allergy is the commonest cause of potentially life- threatening allergic 
reactions (anaphylaxis), a serious systemic hypersensitivity reaction 
that is usually rapid in onset and may cause death.1 Hospital admissions 
due to food- anaphylaxis continue to increase in the UK and elsewhere, 
although reassuringly, the case fatality has not increased.2,3
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Abstract
Introduction: Food hypersensitivity (FHS), including food allergy, coeliac disease and 
food intolerance, is a major public health issue. The Food Standards Agency (FSA), an 
independent UK Government department working to protect public health and con-
sumers’ wider interests in food, sought to identify research priorities in the area of FHS.
Methods: A priority setting exercise was undertaken, using a methodology adapted 
from the James Lind Alliance— the first such exercise with respect to food hyper-
sensitivity. A UK- wide public consultation was held to identify unanswered research 
questions. After excluding diagnostics, desensitization treatment and other questions 
which were out of scope for FSA or where FSA was already commissioning research, 
15 indicative questions were identified and prioritized by a range of stakeholders, rep-
resenting food businesses, patient groups, health care and academia, local authorities 
and the FSA.
Results: 295 responses were received during the public consultation, which were 
categorized into 70 sub- questions and used to define 15 key evidence uncertainties 
(‘indicative questions’) for prioritization. Using the JLA prioritization framework, this 
resulted in 10 priority uncertainties in evidence, from which 16 research questions 
were developed. These could be summarized under the following 5 themes: commu-
nication of allergens both within the food supply chain and then to the end consumer 
(ensuring trust in allergen communication); the impact of socio- economic factors on 
consumers with FHS; drivers of severe reactions; mechanism(s) underlying loss of tol-
erance in FHS; and the risks posed by novel allergens/processing.
Discussion: In this first research prioritization exercise for food allergy and FHS, key 
priorities identified to protect the food- allergic public were strategies to help allergic 
consumers to make confident food choices, prevention of FHS and increasing under-
standing of socio- economic impacts. Diagnosis and treatment of FHS was not consid-
ered in this prioritization.
K E Y W O R D S
allergen labelling, coeliac disease, food allergy, James Lind Alliance, research prioritization
Key messages
• We undertook a food hypersensitivity research priority 
setting exercise for the UK Food Standards Agency.
• This was informed by a public consultation and multi-
ple stakeholder input, but excluded diagnostics and 
treatment
• People with food hypersensitivity identified issues 
around making confident food choices as key research 
priorities.
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The provision of safe food to consumers with FHS is a major pri-
ority for the FSA, an independent Government department work-
ing to protect public health and consumers’ wider interests in food. 
The FSA has been a significant funder of FHS- related research in the 
UK.4 The FSA's Board requested its Science Council, a group of in-
dependent scientific advisers, to undertake a review of its research 
programme on FHS in 2019 and help inform its future direction in 
terms of commissioning research.
Research priorities are often developed without wide and co-
ordinated stakeholder contributions.5 To address this concern, the 
James Lind Alliance (JLA) has developed a methodology for Priority 
Setting Partnerships (PSPs), which brings together patients, carers 
and clinicians to identify and prioritize the evidence uncertainties in 
any given topic area.6 The aim of a PSP is to help ensure that those 
who fund health research are aware of what really matters to pa-
tients, carers and clinicians, the end users of research. The JLA uses 
an adapted nominal group technique; this prevents the domination 
of discussion by a single person and encourages the participation 
of less assertive members, including non- professionals. PSPs have 
been undertaken for numerous chronic diseases including asthma7 
and eczema8 but not for food allergy or food hypersensitivity. 
Industry stakeholders and those with commercial interests are usu-
ally excluded from PSPs. However, in context of the FSA’s remit to 
protect consumers with respect to risks posed by FHS, it was es-
sential to include Food Business Operators and other stakeholders 
involved in the food supply chain. Therefore, in order to meet the 
requirements of the FSA, a research Priority Setting Exercise (PSE) 
was undertaken, adapting PSP principles with the inclusion of indus-
try stakeholders, to identify research priorities for the FSA in the 
area of FHS.
The aim of the PSE was to identify and prioritize the current 
knowledge gaps in providing safe food to individuals with FHS in the 
UK from key stakeholder perspectives, including (but not limited to) 
consumers (both allergic and non- allergic), healthcare professionals, 
regulators, industry and wider stakeholders. The scope of the PSE in-
cluded the following: enabling safe food choices for consumers with 
FHS; practises to handle and produce food safely for those with FHS; 
and behaviours surrounding food safety with specific reference to 
FHS. Although the scope of the PSE did not include underlying health 
delivery (including access to diagnosis and treatment of FHS) as these 
are not within the FSA’s remit, information regarding these issues 
were collected and reported here, although not included in the prior-
itization exercise. In reporting this exercise, we have referred to the 
REPRISE Reporting guideline for priority setting of health research.9
2  |  METHODS
There were 5 stages to the PSE, outlined as follows and in Figure 1:
• Initiation and identification of potential stakeholders: a Steering 
Group made up of members of the FSA Science Council and 
Secretariat was established to write a protocol,10 oversee the PSE 
activity and identify potential stakeholders. The protocol was 
aligned with JLA methodology as per the JLA Guidebook6 and fi-
nalized in December 2019.
• Identifying knowledge gaps: A UK- wide, online consultation of pub-
lic stakeholders was undertaken to identify ‘unanswered ques-
tions’ and knowledge gaps (referred to as ‘evidence uncertainties’) 
relating to the provision of safe food to consumers with FHS.
• Analysis and formulation of research questions: refinement of re-
sponses generated in (ii) to formulate summary questions. This 
work was contracted to Ipsos MORI and overseen by the PSE 
Steering Group.
• Prioritization workshop, where the summary questions identi-
fied in (iii) were prioritized through consensus, with the input 
F I G U R E  1  Outline of methodology
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from representatives of the various stakeholder groups, held in 
September 2020.
• Development of research questions based on the identified priori-
ties, to help the FSA understand the existing evidence base and 
thus the need for future research.
2.1  |  Identification of knowledge gaps and public 
consultation
Five themes were identified by the Steering Group to provide struc-
ture to the PSE:
• Eating out: the consumption of food prepared and served 
away from home, especially at a restaurant, café or take away 
establishment.
• Buying prepacked food that is food that has been prepared in ad-
vance of sale, for example ready meals and packaged sandwiches.
• Handling and Understanding Food— helping consumers to make 
informed choices about buying safe food, which involves the 
following: food preparation, labelling, food/ingredient supply, 
preventing cross- contamination, effective cleaning, testing and 
monitoring to ensure food safety.
• How we interact with food, including changes in how and where 
consumers obtain food today, for example new foods and novel 
allergens, food banks, food business practices, new, reusable 
and biodegradable packaging and online purchasing through the 
Internet.
• Improving knowledge including, questions about the numbers of 
people in the UK affected by food hypersensitivity; or why some 
people develop food hypersensitivity but then outgrow their al-
lergy or sensitivity.
An online public consultation ‘Improving life for people with 
Food Hypersensitivity’ was created using Microsoft Teams and 
launched on 20 February 2020 (see supporting information). The 
public consultation was communicated to over 250 organizations 
via social media channels, targeting the general public, food busi-
nesses, patient groups/charities, religious and cultural organizations, 
the healthcare sector, academia, local authorities and professional 
bodies. Respondents were asked to help identify knowledge gaps re-
lating to FHS in each of the above 5 themes. Responses from the UK 
were automatically collected in Microsoft Excel, cleaned and then 
transferred to Ipsos MORI who were commissioned to analyse the 
responses received, using a 4- stage process as shown in Figure 2.
After excluding out- of- scope questions or those areas in which 
FSA is currently commissioning research, the Steering Group devel-
oped 15 indicative questions to capture the key themes and con-
cerns raised in the public consultation. These were then taken to a 
two- day prioritization workshop in September 2020 (virtual meet-
ing, postponed from early 2020 due to COVID) conducted according 
to the JLA Guidebook.6 Thirty- two stakeholders, representing food 
businesses, patient groups, healthcare professionals and academia, 
local authorities and the FSA, were present. The workshop followed 
the standard JLA workshop method, drawing on an adapted version 
of Nominal Group Technique and consisting of a rounds of mixed- 
stakeholder group discussions and ranking exercises. The workshop 
was facilitated by independent facilitators with experience in the 
JLA priority setting method. Relevant research questions relating 
to the identified priority indicative uncertainties were then devel-
oped by the same attendees at a subsequent workshop. A stan-
dard pro forma, based on a PICO format (Participants, Intervention, 
Comparator, Outcome), was used to guide discussions. No reim-
bursement was provided for participation.
3  |  RESULTS
The public consultation received 295 responses by the time the 
survey closed (a month earlier than anticipated, due to COVID- 19) 
on 26 March 2020, representing a broad group of stakeholders 
(Figure 3), 96% of whom were based in the UK. Responses were cate-
gorized according to ‘tags’ (Table 1) which were then used to identify 
more specific sub- questions. In total, 17 broad themes were gener-
ated, with 70 sub- questions within these themes (see Supporting in-
formation: Table S1; further details appear in the Ipsos MORI report 
available online11). Very broadly the questions and issues identified 
by different stakeholders were similar, although specific types of re-
spondents had slightly greater interest in certain issues.
• Healthcare professionals— allergen contamination (eg due to the 
use of shared production lines); communication of (potential) al-
lergen presence to consumers, including through labelling and 
precautionary allergen (‘may contain’) labels; knowledge and un-
derstanding of FHS; and science underlying the development or 
loss of tolerance resulting in FHS.
• Food business operators (FBOs)— knowledge and understanding 
of FHS; provision of allergen information between FBOs within 
the supply chain and to the end consumer.
• Patients with FHS and their carers— diagnosis and treatment of 
FHS; making safe food choices, including when eating out; mea-
sures to minimize contamination during production; and commu-
nication of allergen information including precautionary allergen 
labels.
The Steering Group then reviewed these sub- questions, and after 
excluding out- of- scope questions or those areas in which FSA is cur-
rently commissioning research (Table 2), 15 indicative questions were 
developed (see supporting information, Table S2) and taken forwards 
for prioritization at the PSE workshop in September 2020 (virtual 
meeting, postponed from early 2020 due to COVID). Using the JLA 
prioritization framework, this resulted in 10 priority indicative uncer-
tainties, from which 16 research questions were developed (Table 3).
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4  |  DISCUSSION
The JLA methodology was originally developed to bring patients and 
clinicians together in a non- hierarchical manner to identify and ad-
dress the most important uncertainties with respect to the effects of 
care and treatments.12 It has since been used to prioritize questions 
for research in over 100 clinical areas internationally. We report the 
outputs from a prioritization exercise using this methodology to 
highlight priority unanswered questions in terms of providing safe 
food to consumers with FHS. This is the first research prioritization 
exercise ever conducted for food allergy and FHS. A major strength 
is the very significant and comprehensive input from patients/
consumers achieved as a result of the initial public consultation. 
Although the focus was on UK consumers, it is likely that many (if not 
all) of the identified indicative uncertainties would apply elsewhere. 
The research questions proposed are not intended to be exhaustive, 
but, rather, reflect the views of the workshop participants in terms 
of areas where addressing the underlying evidence uncertainties 
could help better provide for consumers with FHS. The traditional 
JLA approach ends with the identification of priorities. These tend 
to be broad topic areas which require interpretation and develop-
ment to become tractable propositions for research. We have built 
on this process by incorporating that additional step into the project, 
to identify specific research questions from the priorities, involving 
multiple stakeholders to ensure those questions genuinely reflect 
the concerns of the evidence users.
Healthcare delivery, including therapeutics, are outside the 
FSA’s remit and were therefore considered out of scope. However, 
the public consultation demonstrated that these remain priorities 
for consumers with FHS, and we therefore list these unanswered 
questions in Table 2. A need to improve diagnostics (accuracy, ac-
cessibility) and develop new therapeutics for FHS (including, but not 
limited to allergen desensitization and interventions targeting the 
microbiome) are highlighted. Given that respondents were encour-
aged not to consider issues relating to healthcare provision when 
completing the public consultation, the list of out- of- scope priorities 
should not be considered exhaustive, and a future PSP focussed on 
food allergy management and treatment is justified. We attempted 
as broad a public consultation as possible, using specific targeting 
of community charities and religious organizations to capture the 
inclusion of consumers who might otherwise be excluded, for ex-
ample children/young people and minority groups. Despite this, it is 
possible that some groups may have been under- represented. In this 
respect, it will be interesting to compare the outputs of the ongoing 
F I G U R E  2  Analysis of responses to 
the public consultation into indicative 
questions for the PSE. Further details 
available in the Ipsos MORI report10
F I G U R E  3  Respondents to the public consultation
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COMFA (Core Outcome Measures for Food Allergy) project which 
seeks to develop a set of Core Outcomes for evaluating new treat-
ments for food allergy.13
The priorities identified fit into 5 themes. First, communication 
of allergens both within the food supply chain (between different 
FBOs) and then to the end consumer (ensuring trust in the aller-
gen information available); (ii) the impact of socio- economic factors 
on both the development of FHS and then the risk of more severe 
reactions; (iii) other drivers of severity; (iv) the mechanism(s) by 
which individuals can develop FHS to a previously tolerated food 
(something which is increasingly reported with respect to adult- 
onset FHS); and (v) the risks posed by novel allergens/processing, 
something which is becoming more important given the increasing 
global population and the desire towards sustainability. There are 
many similarities between these themes and those identified by 
PSPs for other related conditions, including asthma, eczema and 
coeliac disease.7,8,14 For coeliac disease, risk communication by 
FBOs (including allergen labelling), diagnostic accuracy, increased 
awareness amongst the general public have also been highlighted 
as priority areas.14
Some of these unanswered questions can be addressed through 
improving the surveillance of FHS reactions occurring in the com-
munity, to inform both current policy and allow the detection of 
new allergen risks (either arising from novel allergens/processes, 
or changes in the consumption patterns of existing allergens) which 
pose a hazard to consumers with FHS. In this respect, the FSA is 
funding the establishment of a UK- wide Anaphylaxis Registry to 
report allergic reactions and developing a Food Allergic Reaction 
Reporting Mechanism to better capture food incidents from FBOs 
and the general public.15
The communication of allergen risk through the food supply 
chain and to the end consumer is partly informed by legislation. The 
public consultation was undertaken prior to the COVID- 19 epidemic, 
which impacted upon the food supply chain; changes in the availabil-
ity of ingredients and the increased use of online ordering and dark 
kitchens have demonstrated potential vulnerabilities which could 
impact on the efficacy of allergen communication. The interpreta-
tion of precautionary allergen (‘may contain’) labels (PAL) remains a 
concern to consumers, FBOs and regulators alike.16 PAL are not spe-
cifically informed by legislation at the current time (although the use 
TA B L E  1  Main themes identified during the public consultation
Themes Mentions (n) Examples of tags in each theme
Packaging and labelling 658 Comprehensive, clear, disclaimers, packaging, allergens, gluten
Allergic consumers 631 Reactions, hypersensitivity, number, frustrations, diagnosis, treatment, Irritable Bowel 
syndrome, coeliac disease
Cross- contamination 397 Manufacturing, processing, products on display, staff behaviour
Information 364 Ingredient lists, digital info, clarity, allergen list
Knowledge / education 306 Better training, guidance, understanding, take it serious, allergy vs. intolerance
Safety 325 Tolerance levels, levels of risk, trust
Allergens 311 14 EU Priority allergens, rapeseed, additives, egg, cow's milk (dairy), nuts
Food 258 Prepacked, more choice, novel food, vegan, vegetarian
Legislation / standardization 239 Ratings, testing, reporting, FSA
Eating out 202 Food preparation, menus, staff knowledge
TA B L E  2  Excluded evidence uncertainties due to out of scope or through being addressed by ongoing FSA- contracted research
Out of scope Addressed by current FSA research
What is the difference between an allergy and an intolerance? How many people are affected by FHS?
Why do healthy eating options include so many allergens? How many hospital/GP visits are due to FHS?
Gluten- free foods: Why do they cost more? Are they ‘better’ for you? What are the most common food allergies/intolerances? Is this 
changing?
Diagnostics: Waiting times, accuracy, access, novel diagnostics and 
genetics
National register or database for allergy incidents/people with FHS
Desensitization treatment for food allergy, including interventions 
targeting the microbiome
Are food allergies/intolerances increasing?
Are staff in food establishments trained in how to use adrenaline 
autoinjector devices?
Is there a link between childhood eczema and food allergy?
Are food allergies in adults treated with the same seriousness as those 
in children?
Thresholds for clinical reactivity, that is how much allergen is needed 
to trigger reactions
Is there a link between food poisoning and the development of FHS?
What is the defined safe level of lead in game birds?
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TA B L E  3  ‘Top 10’ Research questions identified by the PSE
Indicative uncertainty Suggested research question(s) Notes
Risks posed to people with FHS 
by new/novel foods and/or 
processes
In consumers with FHS, what measures are needed to 
monitor for reactions due to:
• new uses of known allergens?
• novel proteins which might induce sensitization and 
thus clinical reactivity?What protocols should the 
FSA use when assessing the risk to consumers with 
FHS posed by novel foods/processes/packaging?
What data exist as to the likelihood of allergenic 
proteins in biobased food contact materials migrating 
into foods?
For example, the use of pea protein in protein 
concentrates, which is often declared only 
as ‘vegetable protein’ in ingredients listing.
For example, wheat- based starch in packaging, 
latex- based binders in packaging and 
sustainable cutlery.
Improving traceability of allergens 
in the food supply chain
How should information be communicated (through the 
food supply chain) to consumers with FHS, to:
• improve consumer confidence in terms of possible 
allergen content?
• reduce the incidence of unintended allergen 
exposure?
The sensitivity and reliability of analytical 
tests was also discussed, but development 
of these and the responsibility to ensure 
such tools are used appropriately was felt 
to be outside the FSA’s research remit.
Risks posed due to shared 
production of foods, and how 
can these be mitigated
What are the health risks to consumers with FHS 
due to allergen cross- contamination during food 
production?
How effective are different control options (such as 
cleaning protocols) in reducing these health risks?
For example, the use of shared ovens (eg 
gluten- free foods cooked in the same oven 
as gluten- containing foods)
Communicating risk, so that 
consumers with FHS can be 
confident that the food they 
are provided is safe
What are the most effective ways for FBOs to 
communicate a level of competence (with respect to 
allergen risk management) to consumers?
Allergen labelling, including 
Precautionary Allergen (‘may 
contain’) labels.
What forms of allergen labelling are effective in order 
for consumers to make informed decisions as to 
whether a food is ‘safe’ for purchase/consumption?
Labelling to inform both what is present, 
what might be present (through cross- 
contamination), and what is not present 
(whether or not a ‘free- from’ claim is 
made).
Informing the FSA as to incidents 
involving food hypersensitivity.
What evidence is there for different reporting systems 
to deliver useful data to regulators that can 
impact on reducing the risk of unintended allergen 
consumption?
What are the barriers that prevent reporting of near 
misses and other incidents to official bodies?
Reporting systems might include the 
following:
• Mandatory/voluntary reporting by 
healthcare professionals.
• Direct reporting by FBOs and the public
• Surveillance of serious incidents e.g. 
coronial system
Impact of co- factors on reaction 
severity
In consumers with FHS, what are the factors which can 
increase the risk of a severe reaction?
How should risk posed by co- factors be communicated 
to those affected by FHS?
Incorporates both general advice to all 
consumers with FHS, and individualised 
advice provided by healthcare 
professionals
Impact of socio- economic factors 
(including race/ethnicity) on 
FHS
What are the socio- economic factors which impact on 
risk in consumers with FHS?
How do cultural attitudes impact on the management 
of FHS?
Includes the following:
• understanding the impact of ethnicity/race 
as confounders
• language impacting on access to effective 
advice and communication of consumer 
needs
• impact on affordability/ accessibility/
availability to safe foods for those with FHS
Impact of environmental 
exposures on risk of 
developing FHS
What are the factors that drive a loss of immune- 
tolerance to food allergens?
(Discussion was also held with respect to the impact of 
disturbances in the microbiome affecting risk of FHS, 
but it was considered that funding research in this 
area would be beyond the scope of the FSA)
Applies to both childhood- and adult- 
onset allergy, for example how common is 
loss of prior tolerance?
Current knowledge of FHS 
amongst the general public
What are the current gaps/inaccuracies in knowledge 
with respect to FHS amongst the general public?
Focus on general public, but also applies to 
specific stakeholders, for example FBOs, 
health care
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of PAL should not be misleading under the General Food Law). Work 
is currently ongoing at a global level to reassess the evidence base 
for use of PAL.17 This should improve scientific rigour and transpar-
ency to the communication of risk posed by unintended allergen 
presence (eg due to cross- contamination during food production), 
allowing consumers with FHS to make more informed and safer food 
choices.
There is a clear impact of socio- economic factors on food allergy 
in the USA18 but the extent to which this may be true in the UK is 
unclear. A London- based study reported a relatively greater increase 
in children diagnosed with peanut allergy over a 14- year period 
(1990– 2004) from non- white backgrounds, compared to egg allergy, 
which could not be explained by improved awareness.19 Another 
study has reported a significantly higher incidence of anaphylaxis 
amongst British South Asians compared with those from a White 
Caucasian background.20 In the EAT study, authors noted a much 
higher rate of food allergy in non- white participants, from 5.3% in 
those from a white background to 19.3% in Asian/black/Chinese 
participants.21 The EAT study also indicated that cultural norms and 
communication may be a factor, with adherence to advice lower in 
those from a non- white background.22 The relationship between 
ethnicity and socio- economic class can be difficult to unpick and can 
also impact on access to health care and communication (which is 
important in terms of dietary advice and risk avoidance). The PSE has 
identified this as a major knowledge gap which should be addressed 
to help resolve the disparities that appear to exist with respect to 
ethnicity and FHS.
Creating a research agenda involves many different drivers: for 
many chronic diseases, research direction is affected by commercial 
interests and the ‘patient voice’ is something which may not figure 
prominently; it is this inequality that the JLA methodology for PSPs 
was designed to address.5 At the same time, the absence of ‘treat-
ments’ for FHS (with management focussed more on avoidance of 
the trigger and rescue medication in the event of accidental reac-
tions) creates different drivers compared with other chronic condi-
tions. Legislation and regulation set a minimum standard for FBOs 
to adhere to, but consumers may not have confidence and trust that 
their needs are being provided for, for instance with respect to the 
purchase of foods from a catering outlet or the use PAL. An FBO can 
be fully compliant with legislation and guidance, yet consumers may 
not feel confident that the FBO can provide them with ‘safe’ food, 
for example, due to poor communication. Improving this requires a 
combination of ‘science push’ and ‘policy pull’, with clear and trans-
parent communication to consumers so that they can develop trust 
in FBOs providing food for them. In undertaking this exercise, we 
hope to have identified key areas where further research and fund-
ing should be targeted, from the perspectives of the various stake-
holders who will be the beneficiaries and end users of FHS research. 
The hope is that this will better provide for the significant proportion 
of the population with FHS and reduce the day- to- day impact of a 
diagnosis of FHS on patients.
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